ELAB ▲ +5.8% - PMGC Holdings Inc. $ELAB - NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications NorthStrive Biosciences, through its partnership with Yuva Biosciences, is advancing an AI-driven drug discovery program with four novel compounds moving toward lead nomination for cardiac disease and obesity therapeutics. The expansion of this program likely drove ELAB shares up 5.8% as investors responded positively to progress in a high-value therapeutic area and validation of the company's AI-discovery platform. 01-SEP-2026 07:45 AM ET